![Early achievement of significant weight loss with naltrexone-bupropion is associated with additional weight loss and improved glycemic control at 1 year in patients with type 2 diabetes - EASO Early achievement of significant weight loss with naltrexone-bupropion is associated with additional weight loss and improved glycemic control at 1 year in patients with type 2 diabetes - EASO](https://cdn.easo.org/wp-content/uploads/2019/01/16195510/ECO2018-Early-achievement-of-significant-weight-loss-with-naltrexone-bupropion-is-associated-with-a.jpg)
Early achievement of significant weight loss with naltrexone-bupropion is associated with additional weight loss and improved glycemic control at 1 year in patients with type 2 diabetes - EASO
![Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes | Future Cardiology Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes | Future Cardiology](https://www.futuremedicine.com/cms/10.2217/fca.15.79/asset/images/medium/figure1.gif)
Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes | Future Cardiology
![Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss - ScienceDirect Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1043661814000449-fx1.jpg)
Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss - ScienceDirect
![Kann das Kombipräparat Bupropion/Naltrexon bei der Behandlung von Adipositas helfen? | Stiftung Gesundheitswissen Kann das Kombipräparat Bupropion/Naltrexon bei der Behandlung von Adipositas helfen? | Stiftung Gesundheitswissen](https://www.stiftung-gesundheitswissen.de/sites/default/files/contentimages/2019_06_27%20Bupropion_Tabelle_Nebenwirkungen_v1_ts.png)